Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys  by Nakao, Kaoru et al.
ble at ScienceDirect
Journal of Pharmacological Sciences 130 (2016) 8e14Contents lists availaHOSTED BY
Journal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull paperNalfuraﬁne hydrochloride, a selective k opioid receptor agonist, has no
reinforcing effect on intravenous self-administration in rhesus
monkeys
Kaoru Nakao a, *, Mikito Hirakata a, Yohei Miyamoto a, Mie Kainoh a, Yoshio Wakasa b,
Tomoji Yanagita c
a Pharmaceutical Research Laboratories, Toray Industries, Inc., 10-1, Tebiro 6-chome, Kamakura, Kanagawa 248-8555, Japan
b Marketing Department, Ina Research Inc., 2148-188 Nishiminowa, Ina-shi, Nagano 399-4501, Japan
c Scientiﬁc Advisor, Ina Research Inc., 2148-188 Nishiminowa, Ina-shi, Nagano 399-4501, Japana r t i c l e i n f o
Article history:
Received 15 June 2015
Received in revised form
20 November 2015
Accepted 24 November 2015
Available online 2 December 2015
Keywords:
Nalfuraﬁne hydrochloride
TRK-820
k opioid receptor
Self-administration
Monkey* Corresponding author. Tel.: þ81 467 32 2111; fax
E-mail address: Kaoru_Nakao@nts.toray.co.jp (K. N
Peer review under responsibility of Japanese Pha
http://dx.doi.org/10.1016/j.jphs.2015.11.008
1347-8613/© 2015 Japanese Pharmacological Society
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Nalfuraﬁne hydrochloride [(E)-N-[17-(cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6b-yl]-
3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride; nalfuraﬁne] is used in Japan as an anti-
pruritic for the treatment of intractable pruritus in patients undergoing hemodialysis or with chronic
liver disease. It is a potent and selective agonist at the k opioid receptor, but also has weak and partial
agonist activity at m opioid receptors. Opioids, especially those acting at m receptors, carry a risk of abuse.
This is an important factor in the consideration of therapeutic risk vs. beneﬁt in clinical use and the
potential for misuse as a public health problem. It is therefore necessary to carefully evaluate the rein-
forcing effects of nalfuraﬁne. To this end, we investigated intravenous self-administration of nalfuraﬁne
in rhesus monkeys. The number of self-administration of nalfuraﬁne at doses of 0.0625, 0.125 and
0.25 mg/kg/infusion was not higher than that of saline in rhesus monkeys that frequently self-
administered pentazocine (0.25 mg/kg/infusion). These results indicate that nalfuraﬁne has no rein-
forcing effect in rhesus monkeys in the intravenous self-administration paradigm.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The selective k opioid receptor agonist nalfuraﬁne hydrochlo-
ride [(E)-N-[17-(cyclopropylmethyl)-4,5a-epoxy-3,14-
dihydroxymorphinan-6b-yl]-3-(furan-3-yl)-N-methylprop-2-
enamide monohydrochloride; nalfuraﬁne] is a well-tolerated and
effective treatment for intractable pruritus in hemodialysis patients
(1e4). It was approved for clinical use in January 2009 by the Jap-
anese Ministry of Health, Labour and Welfare (1,3). Receptor
binding and functional studies of recombinant human and rat
opioid receptors have shown nalfuraﬁne to be a more potent and
selective agonist at k receptors than m and d opioid receptors (3,5).
Opioids, such as morphine, carry a risk of abuse mediated by their
activation of m receptors (6). However, unlike m receptor agonists,
which play a major role in reward and place preference: þ81 467 32 8465.
akao).
rmacological Society.
. Production and hosting by Elseconditioning in animals, selective k agonists generally lack a rein-
forcing effect (7), and are considered not to have the potential to
become drugs of abuse in humans. Although nalfuraﬁne is a se-
lective k agonist, forskolin-stimulated cAMP accumulation studies
have shown that the drug also possesses weak partial agonist ac-
tivity at m receptors (3). Its potential risk of abuse must therefore be
carefully evaluated. No evidence was found of psychological or
physical dependence on nalfuraﬁne in a clinical study in Japanese
hemodialysis patients with severe pruritus (2). However, animal
studies of abuse liability have the advantages of using awider range
of doses and including a positive control drug. Nalfuraﬁne does not
induce conditioned place preference in mice (8) or rats (9), indi-
cating that the drug does not produce a rewarding effect; however,
no studies of nalfuraﬁne self-administration in rats or monkeys
have been reported to date, despite the usefulness of such studies in
evaluating potential abuse liability in humans (7,10e13). Therefore,
the present study was designed to investigate the reinforcing effect
of nalfuraﬁne using intravenous self-administration in rhesus
monkeys.vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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2.1. Animals
Six male and four female adult rhesus monkeys (Macaca
mulatta) were used. The animals were drug-free for 6e18 months
and weighed 3.9e6.7 kg. The monkeys were housed individually at
22e28 C, 40e80% humidity, and under a 12-hour light/dark cycle
(lights on at 7:00 a.m.). The monkeys received approximately 100 g
of solid feed (PS, Oriental Yeast Co., Ltd., Tokyo, Japan) once a day in
Experiment 1, and about 120 g in Experiment 2. Additionally, half a
banana was occasionally given to each monkey in both experi-
ments. Themonkeys were allowed free access to drinking water. All
experiments were conducted in accordance with the principles
speciﬁed by the Institutional Animal Care and Use Committee of Ina
Research Inc.
2.2. Experiment 1: gross behavioral observation after a single
intravenous dose
Six monkeys (three male, three female) were used in a series of
experiments comprising three trials conducted at 1-week intervals
(Table 1). In each trial, the general condition of the animals was
observed prior to drug administration. Animals were assessed for
the following signs, in accordance with the observation criteria of
the test facility: salivation, retching, vomiting, continuous move-
ment, hypoactivity, crouching, prone posture, aggression towards
the observer, reactivity to the observer, reaction towards the
observer by grimacing (a sign of fear), eye closing, pupil dilation or
contraction, slow movement, and ataxia. The animals' general
condition was also observed after drug administration at 0, 15 and
30 min, and 1, 2, 3, 4 and 5 h. Where changes in general condition
persisted for 5 h, those animals were assessed again 24 h after
administration. Food consumption was observed on the day of
administration and the following day, and any changes were
recorded. The diameter of each pupil was estimated by eye; a
change in diameter of approximately 2mm ormore compared with
the pre-administration diameter was recorded as dilation or
contraction.
2.3. Experiment 2: intravenous self-administration
Four monkeys (three male, one female) that had previously self-
administered pentobarbital sodium and/or cocaine intravenously
were used in a series of self-administration experiments. In each
animal, a silicon catheter (outer diameter: 2 mm; inner diameter:
1 mm) was implanted into the jugular or femoral vein under
pentobarbital anesthesia and connected to an automatic drug
infusion apparatus. A red light approximately 5 cm above the self-
administration lever was illuminated when drug solution was
available, and turned off during infusion. Table 2 shows theTable 1
Administration schedules for gross behavioral observation of rhesus monkeys.
Animal ID No. (Sex) Dose of nalfuraﬁne (mg/kg)
1st trial 2nd trial 3rd trial
#1333 (male) 0a 0.5 eb
#1376 (female) 1.0 0a 0.25
#1381 (female) eb 0.5 0a
#1400 (male) 0a 2.0 0.25
#1410 (male) eb 2.0 eb
#1405 (female) 1.0 0a 0a
a Administration of 5% mannitol solution.
b No assignment in corresponding trial.schedule for Experiment 2. In the ﬁrst study period, the self-
administration solution was saline (0.25 mL/kg/infusion). For each
monkey, when self-administration did not exceed 10 infusions/day
for 7 consecutive days, the monkey was allowed to self-administer
pentazocine freely (0.25 mg/kg/infusion). When pentazocine self-
administration reached 35 infusions/day or more for 3 consecu-
tive days, it was replaced with 5% mannitol solution (0.125 mL/kg/
infusion), until self-administration decreased to 10 infusions/day or
fewer for 7 consecutive days. Monkeys were then allowed free
access to nalfuraﬁne self-administration (0.0625, 0.125 or 0.25 mg/
kg/infusion) for 2 weeks at each dose, after which all monkeys
received scheduled intravenous infusions of nalfuraﬁne (0.25 mg/
kg/infusion) at 6-hour intervals for 2 weeks. During this repeated
infusion period, the monkeys were still allowed free access to self-
administered nalfuraﬁne at the same unit dose. When self-
administration occurred, scheduled intravenous infusion of nal-
furaﬁne was postponed by 6 h from the self-administered infusion.
After a 2-week period of scheduled infusions, self-administration of
nalfuraﬁne (0.25 mg/kg/infusion) was observed for an additional 2
weeks. In the ﬁnal study period, nalfuraﬁne was replaced with 5%
mannitol (0.25 mL/kg/infusion) for 1 week of self-administration.
During the pentazocine and nalfuraﬁne study periods, raisins
were attached to the self-administration lever when self-
administration fell to three infusions/day or fewer for 3 consecu-
tive days, to encourage pressing of the lever and maintenance of
self-administration behavior; these data were excluded from the
analysis, and the self-administration periods were subsequently
extended by the number of days that were excluded. Animals were
assessed for hypoactivity and slow movement between 9:00 and
10:00 during each study period.
2.4. Administration
In Experiment 1, each animal was seated on a chair designed for
a monkey and the test solution was administered intravenously
into the forelimb. The injection volume and rate were 0.25 mL/kg
and 1 mL/23 s, respectively. In Experiment 2, the monkeys self-
administered the solution intravenously (14) by pressing the
lever of the self-administration apparatus. Drug or control solution
was infused through a catheter inserted into the vein under a ﬁxed
ratio schedule in which every lever press resulted in an infusion
(FR1). Infusion volume and rate were 0.125 or 0.25 mL/kg and 1mL/
23 s, respectively. There was no limit to the number of infusions
that could be received. Daily self-administration was recorded for
24 h (9:00e9:00 a.m.). On the days in which the test solution was
replaced, observations were interrupted for 1 h (9:00e10:00 a.m.).
2.5. Drugs
Nalfuraﬁne hydrochloride (Toray Industries, Inc., Tokyo, Japan)
was dissolved in 5% mannitol solution to ensure stability of the
drug. Pentazocine (in ampoules of 30 mg/mL; Sosegon® Inj. 30 mg,
Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan) was diluted
with saline.
2.6. Statistical analysis
No statistical analyses were performed in Experiment 1. For data
obtained in Experiment 2, means and standard errors were calcu-
lated for the number of infusions self-administered by each animal
per day, for each solution. A repeated measures analysis of variance
(ANOVA), in which the error terms were assumed to be correlated
within an animal, was used to estimate the mean number of self-
administered infusions per day for study periods 1e9, and to test
the period effects of study periods 2e9 vs. study period 1. The
Table 2
Schedule for intravenous self-administration in rhesus monkeys.
Study
period
Drug Unit dose
(/kg/infusion)
Termination criteria
1 Saline 0.25 mL 10 infusions/day,
7 consecutive days
Y
2 Pentazocine 0.25 mg 35 infusions/day,
3 consecutive days
Y
3 5% mannitol 0.125 mL 10 infusions/day,
7 consecutive days
Y
4 Nalfuraﬁne 0.0625 mg 2 weeks
Y
5 Nalfuraﬁne 0.125 mg 2 weeks
Y
6 Nalfuraﬁne 0.25 mg 2 weeks
Y
7 Nalfuraﬁne 0.25 mg,
6-hour intervala
2 weeks
Y
8 Nalfuraﬁne 0.25 mg 2 weeks
Y
9 5% mannitol 0.25 mL 1 week
a Scheduled repeated infusions at 6-hour intervals when not self-administering.
K. Nakao et al. / Journal of Pharmacological Sciences 130 (2016) 8e1410response variable was the number of self-administrations per day,
and the explanatory variable was the study period as a ﬁxed effect.
The repeated measures ANOVA was carried out using the MIXED
procedure in SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA)
and P < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Gross behavioral observations after a single intravenous dose
(Experiment 1)
Changes in general condition after administration of 5%
mannitol or nalfuraﬁne are summarized in Table 3. After 5%
mannitol administration, increased and/or decreased aggression
towards the observer was noted in ﬁve out of the six monkeys, and
decreased grimacing at the observer was noted in one of these ﬁve
animals. However, most of these signs were transient. No abnormalTable 3
Gross behavioral manifestations after intravenous single-dose administration of
nalfuraﬁne and 5% mannitol in rhesus monkeys.
Signs Number of animals showing each sign
5% Mannitol Nalfuraﬁne (mg/kg)
0.25 mL/kg 0.25 0.5 1 2
(6) (2) (2) (2) (2)
Increase in aggressive behavior
towards observer
3 0 2 0 0
Decrease in aggressive behavior
towards observer
2 0 1 2 1
Decrease in grimacing at observer 1 0 0 1 0
Prone posture 0 0 1 1 1
Slow movement 0 0 1 1 2
Hypoactivity 0 0 2 1 2
Crouching 0 0 2 1 2
Eye closing 0 0 0 1 2
Ataxia 0 0 0 0 1
Jaw slackening 0 0 0 0 2
Salivation 0 0 0 0 2
No changes 1 2 0 0 0
Parentheses indicate total number of animals observed.changes in general conditionwere observed in the sixth animal. No
changes were observed in the two monkeys that received nalfur-
aﬁne at 0.25 mg/kg. Animals that received 0.5, 1.0, or 2.0 mg/kg
nalfuraﬁne showed increased or decreased aggression towards the
observer and/or decreased grimacing at the observer, similar to the
behavior observed after 5%mannitol administration. These changes
were not dose-dependent. Additionally, prone position, slow
movement, hypoactivity, and crouching were observed in animals
that received nalfuraﬁne at a dose of 0.5 mg/kg or higher. Eye closing
was seen at 1 mg/kg or higher, and ataxia, jaw slackening and sali-
vation were observed at 2 mg/kg. Most of the changes observed at
0.5 and 1.0 mg/kg appeared immediately after administration or
within 30 min and persisted for 2e3 h. Conversely, most changes at
2.0 mg/kg appeared 15e30 min after administration and could still
be observed 5 h after administration, but had disappeared by 24 h
post-dose.
3.2. Intravenous self-administration (Experiment 2)
The number of infusions self-administered per day during each
study period are shown in Figs. 1 and 2. During the saline self-
administration period, the means were 0.3e3.1 infusions/day for
the last 7 consecutive days (point estimate of mean (PE) [95%
conﬁdence interval (CI)]: 0.99 [0.44, 1.54] infusions/day). When
saline was replaced with pentazocine, self-administration
increased in all monkeys within 2e4 days after substitution, with
daily means of 41.3e44.0 infusions for the last 3 consecutive days
(PE [95% CI]: 42.26 [41.42, 43.10] infusions/day, P < 0.001 vs. saline).
Next, pentazocine was replaced with 5% mannitol, resulting in
gradual decreases in self-administration in all monkeys, with daily
means of 3.6e6.6 infusions for the last 7 consecutive days (PE [95%
CI]: 5.03 [4.48, 5.57] infusions/day, P < 0.001 vs. saline).When these
monkeys were subsequently allowed free access to self-
administered nalfuraﬁne at 0.0625, 0.125 and 0.25 mg/kg/infusion
for 2 weeks at each dose, the mean number of self-administration
was 0.0e3.1 infusions/day during each period (PE [95% CI] in-
fusions/day, respectively: 1.42 [1.03, 1.81], P ¼ 0.212 vs. saline; 0.53
[0.14, 0.91], P ¼ 0.173 vs. saline; 0.42 [0.04, 0.81], P ¼ 0.096 vs.
saline) and did not exceed that of saline or 5% mannitol. In addition
to having free access to self-administered nalfuraﬁne, the animals
also received scheduled infusions of nalfuraﬁne (0.25 mg/kg/infu-
sion) at 6-hour intervals. During this study period, nalfuraﬁne self-
administration decreased signiﬁcantly (PE [95% CI]: 0.21 [0.81,
0.59] infusions/day, P ¼ 0.022 vs. saline). Furthermore, no increase
in daily nalfuraﬁne self-administration was observed after sched-
uled infusions (PE [95% CI]: 0.35 [0.04, 0.74] infusions/day,
P ¼ 0.060 vs. saline). In the ﬁnal period, nalfuraﬁne was replaced
with 5% mannitol, but no changes in self-administration were
observed (PE [95% CI]: 0.36 [0.19, 0.91] infusions/day, P¼ 0.108 vs.
saline). When self-administration of pentazocine increased, hypo-
activity (in all animals) and slow movement (in two out of four
animals) were observed. Nalfuraﬁne at 0.125 and 0.25 mg/kg/infu-
sion (study periods 5 and 6, respectively) produced hypoactivity in
one and two out of the four animals, respectively. However, these
signs were observed after self-administration of nalfuraﬁne
induced by raisins attached to the self-administration lever
(Table 4).
4. Discussion
Depression-like symptoms including prone posture, slow
movement, hypoactivity, crouching, eye closing, and ataxia were
noted after acute intravenous administration of nalfuraﬁne at doses
of 0.5e2.0 mg/kg, but not 0.25 mg/kg. This is in agreement with
previous studies showing that the k agonists GR89,696 and
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Fig. 1. Study period means for continuous intravenous self-administration of nalfuraﬁne and pentazocine in rhesus monkeys. Study periods: 1, saline self-administration at 0.25 mL/
kg/infusion; 2, pentazocine self-administration at 0.25 mg/kg/infusion; 3, 5% mannitol solution self-administration at 0.125 mL/kg/infusion; 4, 5 and 6, nalfuraﬁne self-
administration at 0.0625, 0.125 and 0.25 mg/kg/infusion, respectively; 7, nalfuraﬁne self-administration at 0.25 mg/kg/infusion with scheduled infusions of the drug at 6-hour in-
tervals at the same unit dose (scheduled infusions postponed by 6 h from the time of each self-administered infusion); 8, nalfuraﬁne self-administration at 0.25 mg/kg/infusion
without scheduled infusions; 9, 5% mannitol solution self-administration at 0.25 mL/kg/infusion. Data are the mean and standard error of daily infusions self-administered by each
animal.
K. Nakao et al. / Journal of Pharmacological Sciences 130 (2016) 8e14 11U69,593 dose-dependently elevate sedation and muscle relaxation
scores in monkeys (15). The reinforcing effects of dependence-
producing drugs may be detected at lower than the minimum
effective dose for gross behavioral changes (16), so we set the unit
dose range for the self-administration part of the study to
0.0625e0.25 mg/kg/infusion.
In a series of intravenous self-administration experiments, four
monkeys were allowed to self-administer nalfuraﬁne at 0.0625,
0.125 and 0.25 mg/kg/infusion, after frequent self-administration of
pentazocine, which has mixed m and k agonist properties in re-
ceptor binding studies and [35S]GTPgS binding studies (17). How-
ever, no difference was observed between self-administration of
nalfuraﬁne and that of saline in any animals. Furthermore, no in-
crease in nalfuraﬁne self-administration was observed during or
after scheduled nalfuraﬁne infusions. Self-administration did not
increase even when nalfuraﬁne was replaced with 5% mannitol in
the ﬁnal study period in this experiment. Retching and vomiting
were observed in twomonkeys following several self-administered
infusions of nalfuraﬁne at 0.25 mg/kg/infusion, so the unit dose
range used in the present study was considered sufﬁcient to
examine the drug's reinforcing effects. Moreover, nalfuraﬁne pro-
duced hypoactivity at 0.125 and 0.25 mg/kg/infusion in study pe-
riods 5 and 6, respectively. Although pentazocine also produced
hypoactivity and slowmovement, robust self-administration of this
drug was observed, indicating that the lack of nalfuraﬁne self-
administration was not due to its non-speciﬁc suppression of mo-
tor function. Together, these results indicate that nalfuraﬁne has no
reinforcing effects in monkeys in the intravenous self-
administration paradigm.
Intravenous injection of 0.25 mg/kg nalfuraﬁne inhibits
scratching behavior induced by intravenous morphine in rhesus
monkeys, indicative of its antipruritic effect (18). This also indicatesthat nalfuraﬁne does not show a reinforcing effect at doses sufﬁ-
cient to produce an antipruritic effect in monkeys. Furthermore,
because nalfuraﬁne is clinically taken orally at doses of 2.5 or 5 mg
(approximately 0.05 or 0.1 mg/kg, respectively, for a 50 kg person) to
relieve intractable pruritus by patients undergoing hemodialysis
(1e3) or with chronic liver disease, the unit dose range of nalfur-
aﬁne used in this study is considered to be equivalent to, or higher
than, that used in clinical practice.
The mesolimbic dopamine system from the ventral tegmental
area to the nucleus accumbens (NAcc), a subregion of the ventral
striatum, plays a critical role in drug dependence (19). In vivo
microdialysis studies have shown that systemic administration of
commonly abused drugs such as amphetamine (20), cannabinoids
(21), heroin (21), cocaine (22), ethanol (23) and nicotine (24), in-
creases extracellular dopamine levels in the NAcc. Dynorphin A and
U-50,488H (endogenous and exogenous selective k agonists,
respectively) decrease extracellular dopamine levels in the NAcc
(25). The effect of nalfuraﬁne on NAcc dopamine levels has not been
reported, but it has been shown that nalfuraﬁne decreases extra-
cellular dopamine levels in the striatum of a rat model of dyskinesia
(26) and in the prefrontal cortex of a rat model of schizophrenia
(27). This suggests that the reason nalfuraﬁne does not induce self-
administration in monkeys is because it does not stimulate the
mesolimbic dopamine system, which is involved in reinforcement.
Nalfuraﬁne has been characterized in vitro as a potent and se-
lective full agonist of the k opioid receptor, with weak partial
agonist activity at the m receptor (3,5). In a [35S]GTPgS binding assay
using a mouse pons/medulla membrane preparation, a much
higher concentration of nalfuraﬁne antagonized the increase of
[35S]GTPgS binding induced by the m agonist DAMGO (28). How-
ever, when co-administered subcutaneously with morphine, nal-
furaﬁne augmented morphine-induced antinociception in mice, in
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Fig. 2. Daily means of continuous intravenous self-administration of nalfuraﬁne and pentazocine in rhesus monkeys. Solid lines represent the time course of the number of self-
administered infusions per day for each animal. Dashed lines represent means for each period estimated by repeated measures of analysis of variance.
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Table 4
Summary of hypoactivity and slow movement during each intravenous self-
administration period.
Study period Number of animals (total, 4) showing each sign
Hypoactivity Slow movement
1 0 0
2 4 2
3 0 0
4 0 0
5 1a 0
6 2a 0
7 0 0
8 0 0
9 0 0
a Signs observed when raisins were attached to the self-administration lever for
maintenance of self-administration behavior.
K. Nakao et al. / Journal of Pharmacological Sciences 130 (2016) 8e14 13the hot-plate test (29) and acetic acid writhing test (30). Further-
more, subcutaneous co-administration of nalfuraﬁne andmorphine
produced an additive antinociceptive effect in the warmwater tail-
withdrawal assay in rhesus monkeys (31). Together, this indicates
that systemic administration of nalfuraﬁne does not act as an
antagonist at m receptors, despite its partial agonist activity. In
contrast, pentazocine is a non-selective partial agonist at m and k
receptors (17), and inhibits morphine-induced antinociception in
the mouse hot-plate test when co-administered subcutaneously
(29), suggesting that systemically administered pentazocine acts as
an antagonist at the m receptor. The difference in properties be-
tween nalfuraﬁne and pentazocine may contribute to their
different effects on reinforcement. The selective full k agonist
U69,593 does not induce self-administration alone, and a combi-
nation of U69,593 and fentanyl, a selective m agonist, produces a
proportion-dependent decrease in fentanyl self-administration (7),
suggesting that abuse liability is inﬂuenced by the balance of m and
k activities in a mixed m/k agonist such as pentazocine.
It has been reported that nalfuraﬁne has a discriminative
stimulus effect in rats. However, whereas U-50,488H generalized to
the discriminative stimulus effects of nalfuraﬁne, nalfuraﬁne did
not generalize completely to those of U-50,488H, indicating that
the subjective effects of nalfuraﬁne and U-50,488H are somewhat
different (32). In contrast, salvinorin A, a selective k agonist and
constituent of the hallucinogenic plant Salvia divinorum, general-
ized completely to the discriminative stimulus effects of U-
50,488H, indicating that the two drugs have similar subjective ef-
fects (33). Moreover, in long-term clinical trials of intravenously or
orally administered nalfuraﬁne, conducted for up to 52 weeks in
hemodialysis patients, there was no evidence of rewarding effects
such as drug-seeking behavior or physical dependence (2,34).
Together, these ﬁndings suggest that nalfuraﬁne has minimal abuse
liability.
5. Conclusions
We have shown that nalfuraﬁne does not produce reinforcing
effects in monkeys at a range of doses including those equivalent to
its antipruritic dose. The data presented here, and those from long-
term clinical trials, suggest that nalfuraﬁne can be used for the
treatment of intractable pruritus in hemodialysis or chronic liver
disease patients with minimal concern regarding the risk of drug
abuse.
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